Ahn H, Lee SY, Jung WJ, Lee KH. Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: A case report and review of literature. World J Stem Cells 2022; 14(4): 303-309 [PMID: PMC9136562 DOI: 10.4252/wjsc.v14.i4.303]
Corresponding Author of This Article
Kye-Ho Lee, PhD, Stem Cell Treatment and Research Institute (STRI), bio Beauty and Health Company (bBHC), No. 72 UN Village-gil, Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
Research Domain of This Article
Neurosciences
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Stem Cells. Apr 26, 2022; 14(4): 303-309 Published online Apr 26, 2022. doi: 10.4252/wjsc.v14.i4.303
Treatment of syringomyelia using uncultured umbilical cord mesenchymal stem cells: A case report and review of literature
Hyunjun Ahn, Sang Yeon Lee, Won-Ju Jung, Kye-Ho Lee
Hyunjun Ahn, Sang Yeon Lee, Kye-Ho Lee, Stem Cell Treatment and Research Institute (STRI), bio Beauty and Health Company (bBHC), Seoul 04420, South Korea
Won-Ju Jung, Stem Cell Treatment, 97.7 Beauty and Health Clinic, Seoul 04420, South Korea
Author contributions: Ahn H, Lee SY, Jung WJ, and Lee KH designed the report; Ahn H and Jung WJ collected the patient’s clinical data; Ahn H, Lee SY, and Jung WJ analyzed the data; Ahn H wrote the manuscript; Lee KH provided professional advice and revised the manuscript; All authors issued final approval for the version to be submitted.
Informed consent statement: The patient involved in this study gave her written informed consent authorizing disclosure of her protected health information.
Conflict-of-interest statement: All authors have no conflicts of interest to declare.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Kye-Ho Lee, PhD, Stem Cell Treatment and Research Institute (STRI), bio Beauty and Health Company (bBHC), No. 72 UN Village-gil, Yongsan-gu, Seoul 04420, South Korea. khlee@stc365.com
Received: December 13, 2021 Peer-review started: December 13, 2021 First decision: January 30, 2022 Revised: February 28, 2022 Accepted: March 26, 2022 Article in press: March 26, 2022 Published online: April 26, 2022 Processing time: 134 Days and 13.8 Hours
Abstract
BACKGROUND
Syringomyelia is a disease caused by the formation of a cavity inside the spinal cord and is accompanied by such symptoms as pain, paresthesia, and urination and defecation disorders, and in severe cases causes various paralyses. Currently, there are only surgical methods for the treatment of syringomyelia, but these methods carry the possibility of failure, recurrence, and side effects.
CASE SUMMARY
The patient was a 59-year-old woman who suffered from pain due to syringomyelia. For treatment, the patient received transplant of uncultured umbilical cord-derived mesenchymal stem cells. As intended, the patient's pain was relieved after treatment. Interestingly, an additional benefit was found in that the size of the cavity also decreased. After 2 years from the last treatment, the patient's cavity had almost completely disappeared and her syringomyelia was deemed cured.
CONCLUSION
Using uncultured umbilical cord-derived mesenchymal stem cells may be a new treatment alternative for syringomyelia.
Core Tip: Syringomyelia has no suitable treatment other than surgical methods, but these methods carry the possibility of failure, recurrence, and side effects. In this study, we treated a patient with syringomyelia using uncultured umbilical cord-derived mesenchymal stem cells. This method could be a new treatment alternative for syringomyelia.
